dc.contributor.author | Hoel, Ida Marie | en_US |
dc.contributor.author | Jørstad, Melissa Davidsen | en_US |
dc.contributor.author | Marijani, Msafiri | en_US |
dc.contributor.author | Ruhwald, Morten | en_US |
dc.contributor.author | Mustafa, Tehmina | en_US |
dc.contributor.author | Dyrhol-Riise, Anne Ma | en_US |
dc.date.accessioned | 2020-01-07T09:59:24Z | |
dc.date.available | 2020-01-07T09:59:24Z | |
dc.date.issued | 2019-03-07 | |
dc.Published | Hoel IM, Jørstad MD, Marijani M, Ruhwald M, Mustafa T, Dyrhol-Riise AM. IP-10 dried blood spots assay monitoring treatment efficacy in extrapulmonary tuberculosis in a low-resource setting. Scientific Reports. 2019;9:3871. | eng |
dc.identifier.issn | 2045-2322 | |
dc.identifier.uri | https://hdl.handle.net/1956/21259 | |
dc.description.abstract | Treatment efficacy is difficult to evaluate in extrapulmonary tuberculosis (EPTB) patients. Interferon-γ inducible protein (IP-)10 has been suggested as a biomarker for response to treatment. We have investigated if IP-10 from dried plasma spots (DPS) or dried blood spots (DBS) can be used in treatment monitoring of EPTB patients in a low-resource setting of Zanzibar. IP-10 levels in plasma, DPS and DBS samples collected before, during (2 months) and after TB treatment of 36 EPTB patients (6 culture and/or Xpert MTB/RIF positive and 30 clinically diagnosed) and 8 pulmonary tuberculosis (PTB) patients, were quantified by an enzyme-linked immunosorbent assay. There was a high positive correlation between IP-10 measured in plasma and DPS and DBS, respectively. We found a significant decline in IP-10 levels from baseline to end of treatment in plasma, DPS and DBS, both in EPTB and PTB patients. The declines were observed already after 2 months in HIV negative patients. In conclusion, the DPS/DBS IP-10 assay allows for easy and manageable monitoring in low-resource settings and our findings suggest that IP-10 may serve as a biomarker for treatment efficacy in EPTB patients, albeit further studies in cohorts of patients with treatment failure and relapse are needed. | en_US |
dc.language.iso | eng | eng |
dc.publisher | Nature Research | eng |
dc.rights | Attribution CC BY 4.0 | eng |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | eng |
dc.subject | Predictive markers | eng |
dc.subject | Tuberculosis | eng |
dc.title | IP-10 dried blood spots assay monitoring treatment efficacy in extrapulmonary tuberculosis in a low-resource setting | en_US |
dc.type | Peer reviewed | |
dc.type | Journal article | |
dc.date.updated | 2019-08-30T09:20:37Z | |
dc.description.version | publishedVersion | en_US |
dc.rights.holder | Copyright 2019 The Author(s) | |
dc.identifier.doi | https://doi.org/10.1038/s41598-019-40458-0 | |
dc.identifier.cristin | 1704774 | |
dc.source.journal | Scientific Reports | |
dc.identifier.citation | Scientific Reports. 2019, 9, 3871. | |